Molecular Pathways in Renal Cell Carcinoma-Rationale for Targeted Treatment

Seminars in Oncology

Volumn 33, Issue 5, 2006, Pages 588-595

  Kim, William Y ^a   Kaelin Jr , William G ^b,c  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; CETUXIMAB; CHEMOKINE RECEPTOR CXCR2; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE INHIBITOR; ERLOTINIB; ERYTHROPOIETIN; FLAVOPIRIDOL; GEFITINIB; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMATINIB; MATRIX METALLOPROTEINASE; SCATTER FACTOR RECEPTOR; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2; VON HIPPEL LINDAU PROTEIN;

ARTICLE; CANCER CELL; CANCER GROWTH; CANCER RISK; CANCER THERAPY; CARCINOGENESIS; CLINICAL TRIAL; GENE EXPRESSION; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; HISTOLOGY; HUMAN; KIDNEY CARCINOMA; META ANALYSIS; METASTASIS; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; VON HIPPEL LINDAU DISEASE;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 33749451610     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.06.001     Document Type: Article

References (94)

1. Cohen H.T., and McGovern F.J. Renal-cell carcinoma. N Engl J Med 353 (2005) 2477-2490
2. Collins E. Intra-ocular growths (two cases, brother and sister, with peculiar vascular new growth, probably retinal, affecting both eyes). Trans Ophthalmol Soc UK 14 (1894) 141-149
3. Kim W.Y., and Kaelin W.G. Role of VHL gene mutation in human cancer. J Clin Oncol 22 (2004) 4991-5004
4. Seizinger B.R., Rouleau G.A., Ozelius L.J., et al. Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 332 (1988) 268-269
5. Latif F., Tory K., Gnarra J., et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260 (1993) 1317-1320
6. Knudson A. Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci U S A 68 (1971) 820-823
7. Lubensky I.A., Gnarra J.R., Bertheau P., et al. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am J Pathol 149 (1996) 2089-2094
8. Zhuang Z., Bertheau P., Emmert-Buck M.R., et al. A microdissection technique for archival DNA analysis of specific cell populations in lesions <1 mm in size. Am J Pathol 146 (1995) 620-625
9. Mandriota S.J., Turner K.J., Davies D.R., et al. HIF activation identifies early lesions in VHL kidneys: Evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1 (2002) 459-468
10. Iliopoulos O., Kibel A., Gray S., et al. Tumour suppression by the human von Hippel-Lindau gene product. Nat Med 1 (1995) 822-826
11. Gnarra J.R., Zhou S., Merrill M.J., et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci U S A 93 (1996) 10589-10594
12. Schoenfeld A., Davidowitz E.J., and Burk R.D. A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proc Natl Acad Sci U S A 95 (1998) 8817-8822
13. Iliopoulos O., Levey A.P., Jaing C., et al. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A 93 (1996) 10595-10599
14. Blankenship C., Naglich J.G., Whaley J.M., et al. Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity. Oncogene 18 (1999) 1529-1535
15. Kaelin Jr. W.G. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2 (2002) 673-682
16. Lee S., Chen D.Y., Humphrey J.S., et al. Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density. Proc Natl Acad Sci U S A 93 (1996) 1770-1775
17. Lee S., Neumann M., Stearman R., et al. Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein. Mol Cell Biol 19 (1999) 1486-1497
18. Semenza G.L. HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol 13 (2001) 167-171
19. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3 (2003) 721-732
20. Hershko A., and Ciechanover A. The ubiquitin system. Annu Rev Biochem 67 (1998) 425-479
21. 2 sensing. Science 292 (2001) 464-468
22. 2-regulated prolyl hydroxylation. Science 292 (2001) 468-472
23. Yu F., White S.B., Zhao Q., et al. HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc Natl Acad Sci U S A 98 (2001) 9630-9635
24. Masson N., William C., Maxwell P.H., et al. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J 20 (2001) 5197-5206
25. Bruick R.K., and McKnight S.L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294 (2001) 1337-1340
26. Epstein A.C., Gleadle J.M., McNeill L.A., et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107 (2001) 43-54
27. Ivan M., Haberberger T., Gervasi D.C., et al. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc Natl Acad Sci U S A 99 (2002) 13459-13464
28. Maxwell P.H., Wiesener M.S., Chang G.W., et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
29. Kondo K., Kim W.Y., Lechpammer M., et al. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 1 (2003) E83
30. Kondo K., Klco J., Nakamura E., et al. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1 (2002) 237-246
31. Maranchie J.K., Vasselli J.R., Riss J., et al. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1 (2002) 247-255
32. Zimmer M., Doucette D., Siddiqui N., et al. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. Mol Cancer Res 2 (2004) 89-95
33. Rankin E.B., Higgins D.F., Walisser J.A., et al. Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice. Mol Cell Biol 25 (2005) 3163-3172
34. Treins C., Giorgetti-Peraldi S., Murdaca J., et al. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem 277 (2002) 27975-27981
35. Hudson C.C., Liu M., Chiang G.G., et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22 (2002) 7004-7014
36. Brugarolas J.B., Vazquez F., Reddy A., et al. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 4 (2003) 147-158
37. Thomas G.V., Tran C., Mellinghoff I.K., et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12 (2006) 122-127
38. Atkins M.B., Hidalgo M., Stadler W.M., et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22 (2004) 909-918
39. Isaacs J.S., Jung Y.J., Mimnaugh E.G., et al. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem 277 (2002) 29936-29944
40. Kong X., Lin Z., Liang D., et al. Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1{alpha}. Mol Cell Biol 26 (2006) 2019-2028
41. Kaelin WG: von Hippel-Lindau-associated malignancies: Mechanisms and therapeutic opportunities. Drug Discovery Today (in press)
42. Jiang Y., Zhang W., Kondo K., et al. Gene expression profiling in a renal cell carcinoma cell line: Dissecting VHL and hypoxia-dependent pathways. Mol Cancer Res 1 (2003) 453-462
43. Galban S., Fan J., Martindale J.L., et al. von Hippel-Lindau protein-mediated repression of tumor necrosis factor alpha translation revealed through use of cDNA arrays. Mol Cell Biol 23 (2003) 2316-2328
44. Caldwell M.C., Hough C., Furer S., et al. Serial analysis of gene expression in renal carcinoma cells reveals VHL-dependent sensitivity to TNFalpha cytotoxicity. Oncogene 21 (2002) 929-936
45. Ohm J.E., Gabrilovich D.I., Sempowski G.D., et al. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 101 (2003) 4878-4886
46. Gabrilovich D.I., Ishida T., Nadaf S., et al. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 5 (1999) 2963-2970
47. Fox S.B., Turley H., Cheale M., et al. Phosphorylated KDR is expressed in the neoplastic and stromal elements of human renal tumours and shuttles from cell membrane to nucleus. J Pathol 202 (2004) 313-320
48. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
49. Rini B., Rixe R., Bukowski R., et al. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell carcinoma (RCC). J Clin Oncol 23 (2005) 380s (abstr 4509)
50. Motzer RJ, Michaelson MD, Redman BG, et al: Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). ASCO 2005. Orlando, FL: ASCO
51. Escudier B, Eisen T, Stadler WM, et al: Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). ASCO 2005. Orlando, FL: ASCO
52. Ratain MJ, Eisen T, Stadler WM, et al: Final findings from a Phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). American Society of Clinical Oncology 2005 Annual Meeting. Orlando, FL: ASCO
53. Hood J.D., Bednarski M., Frausto R., et al. Tumor regression by targeted gene delivery to the neovasculature. Science 296 (2002) 2404-2407
54. Kourembanas S., Hannan R.L., and Faller D.V. Oxygen tension regulates the expression of the platelet-derived growth factor-B chain gene in human endothelial cells. J Clin Invest 86 (1990) 670-674
55. Bergers G., and Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3 (2003) 401-410
56. Bergers G., et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111 (2003) 1287-1295
57. Benjamin L.E., Golijanin D., Itin A., et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103 (1999) 159-165
58. Castillo M., Petit A., Mellado B., et al. C-kit expression in sarcomatoid renal cell carcinoma: Potential therapy with imatinib. J Urol 171 (2004) 2176-2180
59. Zigeuner R., Ratschek M., and Langner C. Kit (CD117) immunoreactivity is rare in renal cell and upper urinary tract transitional cell carcinomas. Br J Urol Int 95 (2005) 315-318
60. Sengupta S., Cheville J.C., Corless C.L., et al. Rare expression of KIT and absence of KIT mutations in high grade renal cell carcinoma. J Urol 175 (2006) 53-56
61. Gunaratnam L., Morley M., Franovic A., et al. Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells. J Biol Chem 278 (2003) 44966-44974
62. de Paulsen N., Brychzy A., Fournier M.C., et al. Role of transforming growth factor-alpha in von Hippel-Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: A possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc Natl Acad Sci U S A 98 (2001) 1387-1392
63. Knebelmann B., Ananth S., Cohen H.T., et al. Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor. Cancer Res 58 (1998) 226-231
64. Smith K., Gunaratnam L., Morley M., et al. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/± renal cancer. Cancer Res 65 (2005) 5221-5230
65. Prewett M., Rothman M., Waksal H., et al. Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Clin Cancer Res 4 (1998) 2957-2966
66. Rowinsky E.K., Schwartz G.H., Gollob J.A., et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 22 (2004) 3003-3015
67. Motzer R.J., Amato R., Todd M., et al. Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 21 (2003) 99-101
68. Hainsworth J.D., Sosman J.A., Spigel D.R., et al. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 23 (2005) 7889-7896
69. Genentech announces preliminary results from randomized phase II trial of avastin and tarceva in kidney cancer. Press release (2005), Genentech, South San Francisco, CA
70. Lee Y.S., Vortmeyer A.O., Lubensky I.A., et al. Coexpression of erythropoietin and erythropoietin receptor in von Hippel-Lindau disease-associated renal cysts and renal cell carcinoma. Clin Cancer Res 11 (2005) 1059-1064
71. Westenfelder C., and Baranowski R.L. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 58 (2000) 647-657
72. Kundu S.D., Kim I.Y., Zelner D., et al. Absence of expression of transforming growth factor-beta type II receptor is associated with an aggressive growth pattern in a murine renal carcinoma cell line, Renca. J Urol 160 (1998) 1883-1888
73. Wykoff C.C., Sotiriou C., Cockman M.E., et al. Gene array of VHL mutation and hypoxia shows novel hypoxia-induced genes and that cyclin D1 is a VHL target gene. Br J Cancer 90 (2004) 1235-1243
74. Zatyka M., da Silva N.F., Clifford S.C., et al. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Cancer Res 62 (2002) 3803-3811
75. Raval R.R., Lau K.W., Tran M.G., et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 25 (2005) 5675-5686
76. Bindra R.S., Vasselli J.R., Stearman R., et al. VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Res 62 (2002) 3014-3019
77. Van Veldhuizen P.J., Faulkner J.R., Lara Jr. P.N., et al. A phase II study of flavopiridol in patients with advanced renal cell carcinoma: Results of Southwest Oncology Group Trial 0109. Cancer Chemother Pharmacol 56 (2005) 39-45
78. Shimamura T., Lowell A.M., Engelman J.A., et al. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res 65 (2005) 6401-6408
79. Hayashi M., Sakata M., Takeda T., et al. Up-regulation of Met expression through HIF-1{alpha} is involved in trophoblast invasion under low-oxygen tension. Endocrinology 146 (2005) 4682-4689
80. Pennacchietti S., Michieli P., Galluzzo M., et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3 (2003) 347-361
81. Yamauchi M., Kataoka H., Itoh H., et al. Hepatocyte growth factor activator inhibitor types 1 and 2 are expressed by tubular epithelium in kidney and down-regulated in renal cell carcinoma. J Urol 171 (2004) 890-896
82. Pisters L.L., el-Naggar A.K., Luo W., et al. C-met proto-oncogene expression in benign and malignant human renal tissues. J Urol 158 (1997) 724-728
83. Schmidt L., Duh F.M., Chen F., et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16 (1997) 68-73
84. Petrella B.L., Lohi J., and Brinckerhoff C.E. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma. Oncogene 24 (2005) 1043-1052
85. Koochekpour S., Jeffers M., Wang P.H., et al. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol 19 (1999) 5902-5912
86. Bergers G., Brekken R., McMahon G., et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2 (2000) 737-744
87. Miyake H., Hara I., Gohji K., et al. Relative expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in mouse renal cell carcinoma cells regulates their metastatic potential. Clin Cancer Res 5 (1999) 2824-2829
88. Kallakury B.V., Karikehalli S., Haholu A., et al. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 7 (2001) 3113-3119
89. Staller P., Sulitkova J., Lisztwan J., et al. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 425 (2003) 307-311
90. Zagzag D., Krishnamachary B., Yee H., et al. Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res 65 (2005) 6178-6188
91. Ceradini D.J., Kulkarni A.R., Callaghan M.J., et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 10 (2004) 858-864
92. Kang H., Watkins G., Parr C., et al. Stromal cell derived factor-1: Its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer. Breast Cancer Res 7 (2005) R402-R410
93. Scala S., Ottaiano A., Ascierto P.A., et al. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res 11 (2005) 1835-1841
94. Kim J., Takeuchi H., Lam S.T., et al. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol 23 (2005) 2744-2753